These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 9123739

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Androgen deprivation prior to radical prostatectomy for T2b and T3 prostate cancer.
    Soloway MS, Hachiya T, Civantos F, Murphy WM, Gomez CC, Ruiz HE.
    Urology; 1994 Feb; 43(2 Suppl):52-6. PubMed ID: 7509535
    [Abstract] [Full Text] [Related]

  • 44. Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis.
    Koie T, Mitsuzuka K, Yoneyama T, Narita S, Kawamura S, Kaiho Y, Tsuchiya N, Tochigi T, Habuchi T, Arai Y, Ohyama C, Yoneyama T, Tobisawa Y.
    Int J Clin Oncol; 2015 Oct; 20(5):1018-25. PubMed ID: 25681879
    [Abstract] [Full Text] [Related]

  • 45.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. [Prognostic factors in patients with prostatic cancer treated with neoadjuvant hormonal therapy and radical prostatectomy].
    Villavicencio Mavrich H, Chéchile Toniolo G, Salinas Duffo D, Muñoz Plaza J, Sorraca Ibáñez YJ.
    Arch Esp Urol; 1996 Oct; 49(8):797-806. PubMed ID: 9065276
    [Abstract] [Full Text] [Related]

  • 48. Estimation of total PSA with a supersensitive PSA-assay during neo-adjuvant-chemotherapy of prostate cancer before radical resection of prostate.
    Spitz J, Enzmann T, Müller W, Weidenfeld M, Köllermann M.
    Anticancer Res; 1999 Oct; 19(4A):2637-40. PubMed ID: 10470209
    [Abstract] [Full Text] [Related]

  • 49. The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy.
    Diamond T, Campbell J, Bryant C, Lynch W.
    Cancer; 1998 Oct 15; 83(8):1561-6. PubMed ID: 9781950
    [Abstract] [Full Text] [Related]

  • 50. Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level.
    Tiguert R, Rigaud J, Lacombe L, Laverdière J, Fradet Y.
    J Urol; 2003 Aug 15; 170(2 Pt 1):447-50. PubMed ID: 12853796
    [Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Maximum androgen deprivation prior to radical retropubic prostatectomy in patients with stage T3 adenocarcinoma of the prostate.
    Voges GE, Mottrie AM, Fichtner J, Mappes C, Störkel S, Stöckle M, Hohenfellner R.
    Eur Urol; 1995 Aug 15; 28(3):209-14. PubMed ID: 8536774
    [Abstract] [Full Text] [Related]

  • 54. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer.
    Zincke H, Lau W, Bergstralh E, Blute ML.
    J Urol; 2001 Dec 15; 166(6):2208-15. PubMed ID: 11696737
    [Abstract] [Full Text] [Related]

  • 55. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer.
    Prayer-Galetti T, Sacco E, Pagano F, Gardiman M, Cisternino A, Betto G, Sperandio P.
    BJU Int; 2007 Aug 15; 100(2):274-80. PubMed ID: 17355369
    [Abstract] [Full Text] [Related]

  • 56. A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy.
    Sayyid RK, Evans A, Hersey K, Maloni R, Hurtado-Coll A, Kulkarni G, Finelli A, Zlotta AR, Hamilton R, Gleave M, Fleshner NE.
    Clin Cancer Res; 2017 Apr 15; 23(8):1974-1980. PubMed ID: 27756786
    [Abstract] [Full Text] [Related]

  • 57. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease.
    Spahn M, Briganti A, Capitanio U, Kneitz B, Gontero P, Karnes JR, Schubert M, Montorsi F, Scholz CJ, Bader P, van Poppel H, Joniau S, European Multicenter Prostate Cancer Clinical and Translational Research Group.
    J Urol; 2012 Jul 15; 188(1):84-90. PubMed ID: 22578727
    [Abstract] [Full Text] [Related]

  • 58. Long-term results of neoadjuvant hormonal therapy prior to radical prostatectomy in patients with clinically localized prostate cancer: biochemical and pathological effects.
    Hara I, Miyake H, Hara S, Gotoh A, Eto H, Arakawa S, Kamidono S.
    Hinyokika Kiyo; 2001 Jul 15; 47(7):453-8. PubMed ID: 11523127
    [Abstract] [Full Text] [Related]

  • 59. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer.
    Clark PE, Peereboom DM, Dreicer R, Levin HS, Clark SB, Klein EA.
    Urology; 2001 Feb 15; 57(2):281-5. PubMed ID: 11182337
    [Abstract] [Full Text] [Related]

  • 60. Use of neoadjuvant androgen deprivation therapy in clinically localized prostate cancer.
    Fair WR, Aprikian AG, Cohen D, Sogani P, Reuter V.
    Clin Invest Med; 1993 Dec 15; 16(6):516-22. PubMed ID: 8013156
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.